United States Patent 7,375,111: What is claimed, how broad it is, and where competitors can still win
What does US 7,375,111 claim, in plain scope terms?
US Patent 7,375,111 claims a single oral fixed-combination weight-loss composition that uses:
- Bupropion (or a pharmaceutically acceptable salt) in a sustained release (SR) formulation in an amount effective to induce weight loss; and
- Naltrexone (or a pharmaceutically acceptable salt) in a sustained release (SR) formulation in an amount effective to enhance the weight-loss effect of bupropion.
The independent claim structure is the same in claim 1 and claim 5:
- Claim 1 is a “composition” claim with SR bupropion + SR naltrexone in fixed combination in a single oral dosage form.
- Claim 5 is a “pharmaceutical composition” claim that explicitly recites a pharmaceutically acceptable excipient/diluent/carrier plus the same core SR fixed-combination requirement.
This patent’s novelty is expressed through four structural claim constraints:
- Two active ingredients: bupropion + naltrexone (both must be present)
- Both are SR formulations (not immediate-release)
- Fixed combination in a single oral dosage form (not separate pills)
- Use is weight loss / enhancing weight-loss effect via defined dose ranges in dependent claims
Independent claim scope (Claims 1 and 5): where the boundaries sit
Claim 1 (composition)
Key limitations:
- “single oral dosage form fixed combination”
- bupropion SR in an amount effective to induce weight loss
- naltrexone SR in an amount effective to enhance the weight loss effect of bupropion
- The “enhance” element is functional, but tied to the defined pairing and SR format
Claim 5 (pharmaceutical composition)
Key limitations:
- “single oral fixed combination dosage form”
- SR bupropion + SR naltrexone
- Includes “pharmaceutically acceptable excipient, diluent, or carrier”
- Functionally the same: naltrexone amount is effective to enhance bupropion’s weight-reducing effect
Practical interpretation for enforcement:
Any product that delivers both actives together in one oral unit and uses SR delivery for both, and where formulation and dosing fall within “amount effective to induce/ enhance,” is within the claim’s core boundary.
Dose-range dependent claims: how much narrowing the patent actually does
Claims 2-4 and 6-8 add dose bands. These do not change the structural requirements (SR, fixed combination, single oral dosage form), but they can narrow infringement analysis depending on product strength.
| Claim |
What varies |
Recited naltrexone range |
Recited bupropion range |
Combination present? |
| 2 |
Naltrexone range |
5 mg to 50 mg |
not specified |
Yes, with bupropion (from claim 1) |
| 3 |
Bupropion range |
not specified |
30 mg to 500 mg |
Yes, with naltrexone (from claim 1) |
| 4 |
Both ranges |
5 mg to 50 mg |
30 mg to 500 mg |
Yes |
| 6 |
Naltrexone range |
5 mg to 50 mg |
not specified |
Yes, with bupropion (from claim 5) |
| 7 |
Bupropion range |
not specified |
30 mg to 500 mg |
Yes, with naltrexone (from claim 5) |
| 8 |
Both ranges |
5 mg to 50 mg |
30 mg to 500 mg |
Yes |
What this means in practice:
- If an accused product uses an SR fixed combination in one oral dosage form but does not hit the dependent bands, it can still fall under independent claim 1 or 5 because those claims use “amount effective to” language rather than hard numeric ranges.
- The numeric bands mainly strengthen patent position for products that sit inside 5–50 mg naltrexone and 30–500 mg bupropion per unit.
How does the claim language map to product design choices competitors can make?
1) “Sustained release formulation” is a gating requirement
The patent requires that both bupropion and naltrexone are in sustained release formulations.
Product designs that can reduce exposure:
- Immediate-release for either bupropion or naltrexone (breaking the “SR formulation” requirement).
- Different dosage architecture where one drug is SR and the other is not, even if the same tablet contains both.
Product designs that increase exposure:
- Single tablet/capsule where both actives have SR characteristics (commonly multilayer tablet, coated pellets, matrix systems, or other controlled-release formats) so that both meet “sustained release” in claim construction.
2) “single oral dosage form fixed combination” prevents “separate pill” workarounds
The claims require a single oral dosage form that is a fixed combination.
Product designs that can reduce exposure:
- Co-administration of separate immediate-release and/or separate SR units (even in the same regimen) is not a “single oral dosage form fixed combination.”
- Packaged combinations where the actives are in separate dosage forms inside one kit also aim to avoid “single oral dosage form.”
Product designs that increase exposure:
- A single tablet/capsule containing both bupropion and naltrexone in SR form.
3) The functional “effective to” language broadens the independent claims
Independent claims are not limited to the dependent numeric ranges. They cover any dosing that is “effective to induce weight loss” and “effective to enhance” bupropion’s effect.
That typically creates an enforcement posture where the patentee can argue:
- the product achieves weight-loss in humans; and
- naltrexone enhances bupropion’s effect relative to bupropion alone (or at least that the formulation is designed for that pharmacologic goal).
Claim-set design: why this patent is positioned for broad capture
What coverage structure does it use?
The patent uses:
- Two independent claims in parallel (composition vs pharmaceutical composition)
- Eight total claims, with dependent claims focused on dose ranges rather than formulation mechanics (no detailed pellet/coating/matrix limitations appear in the claim text you provided)
What is not explicitly claimed (based on your claim text)
Your claim language does not specify:
- a particular SR technology (matrix vs coating, pellets vs film layers)
- a dissolution rate profile
- a particular form factor (tablet vs capsule vs granules inside capsule)
- particular excipient types beyond “pharmaceutically acceptable excipient/diluent/carrier”
That omission matters: it lets the patentee argue for a broad interpretation of “sustained release formulation” without being pinned to a single manufacturing method.
Patent landscape for the bupropion + naltrexone weight-loss combination (US enforcement view)
How this patent fits against the typical competitive field
A company designing bupropion/naltrexone for weight loss in the US generally confronts three overlapping patent layers:
-
Active pairing and combination dose regimens
Where a patent like 7,375,111 targets bupropion SR + naltrexone SR in a single oral fixed combination dosage form.
-
Formulation-specific SR controls
Separate patents can claim the specific SR delivery system, dissolution behavior, or manufacturing approaches. If a competitor breaks “SR” for one drug, it may still face formulation patents for the other drug’s controlled release.
-
Orphaned design-around areas
Products can aim to avoid fixed-combination single-dosage form, SR for both drugs, or the numeric dose bands.
Enforcement leverage points implied by the claim set
Even without a full family map, the claim text points to leverage:
- The SR requirement is crisp and product-auditable.
- The single oral fixed-combination requirement is crisp and packaging-auditable.
- The dose bands in dependent claims align with common commercial titration approaches for bupropion/naltrexone products.
High-probability infringement scenarios (based on the claim constraints)
Scenario A: Single SR tablet/capsule containing both actives
- Bupropion SR: present
- Naltrexone SR: present
- One dosage unit delivers both drugs together
- Doses fall within or outside dependent ranges
Likelihood: High under claim 1/5 if “sustained release” and “amount effective” are satisfied.
Scenario B: SR for both actives but product doses below dependent ranges
- The product still contains bupropion SR + naltrexone SR in one oral fixed combination
- Naltrexone or bupropion strengths outside 5–50 mg or 30–500 mg
Likelihood: Medium-to-high under claim 1/5 because independent claims are “amount effective,” not limited to the bands.
Scenario C: SR for only one active
- Naltrexone is immediate release; bupropion is SR, or vice versa
Likelihood: Lower for claims 1/5 if courts construe “sustained release formulation” as requiring SR for both actives.
Scenario D: Separate dosage forms
- One pill is bupropion SR, another is naltrexone SR, taken together
Likelihood: Lower because the claims require “single oral dosage form fixed combination.”
Design-around map: where competitors can focus
The three most defensible design-around levers
- Break the “single oral dosage form fixed combination”
- Use separate tablets/capsules.
- Break SR status for one active
- Make one drug immediate release or non-sustained in its release profile.
- Stay outside SR + single-form constraints simultaneously
- Combination of separate dosage forms and non-SR for one active best reduces reach.
The weak lever
- Staying outside the dependent dose ranges alone.
- Because claims 1 and 5 cover “amount effective” broadly.
What business decisions should follow from the claim scope
For R&D teams
- During formulation development, document:
- controlled-release performance for both actives
- whether the final product is a single dosage form fixed combination
- If the strategy is to avoid the patent, target design-around lever(s) above rather than relying on dose-band differences.
For licensing and diligence
- In product diligence, focus on:
- whether the marketed dosage unit contains both drugs together
- whether both meet the SR definition in claim construction
- the per-unit strength bands (even though not strictly required for independent claim coverage)
Key Takeaways
- US 7,375,111 claims a single oral fixed-combination product where both bupropion and naltrexone are sustained release formulations for weight loss.
- Dependent claims lock in dosage bands: naltrexone 5–50 mg and bupropion 30–500 mg (but independent claims can still cover products outside these bands via “amount effective” language).
- The most potent infringement determinants are structural: single dosage form fixed combination and SR for both actives.
- Design-arounds with the highest practical traction are to use separate dosage forms and/or make one active non-SR, rather than relying on strength selection alone.
FAQs
-
Does the patent require both bupropion and naltrexone to be sustained release?
Yes. Claims 1 and 5 recite sustained release formulations for each active.
-
Is a single capsule or tablet required?
Yes. The claims require a single oral dosage form fixed combination.
-
Do the dose ranges in dependent claims define the whole patent scope?
No. The independent claims use “amount effective to” language, so products can still be within scope even if outside the dependent numeric ranges.
-
Can co-administration using separate pills avoid infringement?
It can reduce risk because the claims require a single oral fixed-combination dosage form.
-
What is the key product test for freedom-to-operate under this patent’s claims?
Whether the marketed unit delivers both SR bupropion and SR naltrexone together in one oral fixed-combination dosage form.
References
[1] US Patent 7,375,111. Claims provided by user.
